SGLT2抑制剂对CKD合并2型糖尿病患者胰岛素使用的影响:CREDENCE试验分析
该研究为CREDENCE试验的事后分析,评估卡格列净对CKD合并2型糖尿病患者胰岛素使用的影响。4401例参与者中65.5%基线使用胰岛素,中位治疗2.0年期间卡格列净使胰岛素起始或剂量强化需求降低19%(HR 0.81,95%CI 0.71-0.93),且不受基线肾功能或白蛋白尿影响。
要点
- 卡格列净使胰岛素起始或>25%剂量强化风险降低19%(HR 0.81)
- 卡格列净组更常实现>50%持续胰岛素减量(HR 1.49)
- 卡格列净对肾脏、心血管及安全性结局的影响不受基线胰岛素使用影响
核心结论
- 在CKD合并2型糖尿病患者中,卡格列净可减少胰岛素使用,且效果不受基线肾功能影响。
- 该结果支持卡格列净用于CKD患者,不仅保护终末器官,还可改善血糖控制并减少胰岛素暴露及其不良反应。
研究设计与样本
- CREDENCE试验的事后分析,共纳入4401例CKD合并2型糖尿病参与者。
- 使用Cox回归模型评估卡格列净与安慰剂对胰岛素使用(起始、剂量强化、减量及停用)的影响。
- 主要结局为胰岛素起始或>25%胰岛素剂量强化(分别针对基线未使用和使用胰岛素者)。
主要发现
- 4401例参与者中2884例(65.5%)基线使用胰岛素,该人群eGFR更低、白蛋白尿更高、糖尿病病程更长(均P<.001)。
- 中位治疗2.0年期间,卡格列净较安慰剂使胰岛素起始或>25%剂量强化需求降低19%(HR 0.81,95%CI 0.71-0.93)。
- 该效果不受基线肾功能或白蛋白尿影响(交互作用P均>.10)。
- 卡格列净组更常实现>50%持续胰岛素减量(HR 1.49,95%CI 1.15-1.91),但两组胰岛素停用无差异。
- 卡格列净对肾脏、心血管及安全性结局的影响不受基线胰岛素使用影响(交互作用P均>.05)。
临床怎么用
- 对CKD合并2型糖尿病患者,卡格列净可在肾脏保护之外减少胰岛素起始和剂量强化需求。
- 基线使用胰岛素且肾功能较差、白蛋白尿较高的CKD患者仍可从卡格列净中获益,无需因胰岛素使用而调整用药决策。
局限性
- 本研究为CREDENCE试验的事后分析。
- 中位治疗观察期为2.0年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insulin is a mainstay treatment for diabetes, but its use is associated with weight gain and hypoglycaemia. Data on the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on insulin use in people with chronic kidney disease (CKD) are limited. METHODS: We conducted a post hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial. Effects of canagliflozin versus placebo on insulin use (initiation, dose intensification, reduction and discontinuation) in people with CKD and type 2 diabetes were evaluated using Cox regression models. The primary outcome was insulin initiation or a >25% insulin dose intensification (in those not receiving and receiving insulin at baseline, respectively). Effects on kidney, cardiovascular and safety outcomes by baseline insulin use were also assessed. RESULTS: Among 4401 participants, 2884 (65.5%) were receiving insulin at baseline; these participants were more likely to have lower estimated glomerular filtration rate, higher albuminuria and a longer duration of diabetes (all P < .001). Over a median on-treatment period of 2.0 years, canagliflozin reduced the need for insulin initiation or a >25% dose intensification by 19% compared with placebo {hazard ratio [HR] 0.81 [95% confidence interval (CI) 0.71-0.93]}, irrespective of baseline kidney function or albuminuria (both P-interaction > .10). Sustained insulin dose reductions of >50% were achieved more frequently with canagliflozin than placebo [HR 1.49 (95% CI 1.15-1.91)], although no difference in insulin discontinuation was observed between treatment arms. Effects of canagliflozin on kidney, cardiovascular and safety outcomes were consistent regardless of baseline insulin use (all P-interaction > .05). CONCLUSIONS: In CKD and type 2 diabetes, canagliflozin reduces insulin use with consistent effects regardless of baseline kidney function. This supports the use of canagliflozin in people with CKD, not only for end-organ protection, but also to improve glycaemic control and reduce exposure to insulin and its associated adverse effects.
引用
- Beal B, Buizen L, Yeung EK, et al. Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial. Nephrol Dial Transplant. 2025. PMID: 40036884. doi:10.1093/ndt/gfaf044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。